This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Sep 1;29(25):3493-4; author reply 3494-5.

doi: 10.1200/JCO.2011.37.0312. Epub 2011 Aug 1.

Are we getting closer to using methotrexate in an optimal manner?

Barton A Kamen, Joseph R Bertino, John S Holcenberg, W Archie Bleyer

PMID: 21810689
DOI: 10.1200/JCO.2011.37.0312

Comment

Are we getting closer to using methotrexate in an optimal manner?

Barton A Kamen et al. J Clin Oncol. 2011.

. 2011 Sep 1;29(25):3493-4; author reply 3494-5.

doi: 10.1200/JCO.2011.37.0312. Epub 2011 Aug 1.

Authors

Barton A Kamen, Joseph R Bertino, John S Holcenberg, W Archie Bleyer

PMID: 21810689
DOI: 10.1200/JCO.2011.37.0312

No abstract available

PubMed Disclaimer

Comment on

Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.
Mikkelsen TS, Sparreboom A, Cheng C, Zhou Y, Boyett JM, Raimondi SC, Panetta JC, Bowman WP, Sandlund JT, Pui CH, Relling MV, Evans WE. Mikkelsen TS, et al. J Clin Oncol. 2011 May 1;29(13):1771-8. doi: 10.1200/JCO.2010.32.5340. Epub 2011 Mar 28. J Clin Oncol. 2011. PMID: 21444869 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.